By HotStockRockets | Thursday 13 June 2019
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Drug development & clinical trial services company Venn Life Sciences (VENN) has announced audited 2018 results, a placing and acquisition (in which Tom Winnifrith has shares) progress which has seen the shares restored to trading – and we have chatted with CEO Cathal Friel…
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.
Filed under:
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Time left: 00:39:41